Pfizer
plans to test a combination of three cancer drugs in humans next
year. The trial will be one of the first to test three
immunotherapies at the same time, and will involve giving a small group
of patients a cocktail of drugs to determine whether the combination is
safe, and whether it can shrink tumors in those suffering from solid
cancers.
The Cancer therapy will add Avelumab, a checkpoint inhibitor to two other drugs, Utomilumab and another code-named OX40. These drugs cost roughly $150,000 per patient per year!
No comments:
Post a Comment